Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Texas A&M System contract designates the CDMO’s Texas facility for emergency federal use.
January 11, 2021
By: Contract Pharma
Contract Pharma Staff
Fujifilm Diosynth Biotechnologies, and the Texas A&M University System Center for Innovation in Advanced Development & Manufacturing (CIADM), have begun production on two different COVID-19 vaccine candidates with support from the U.S. government to meet Operation Warp Speed goals. Fujifilm Diosynth Biotechnologies Texas, a subcontractor of the CIADM, recently completed its capacity expansion at its Flexible Biomanufacturing Facility in College Station, TX, to accommodate large-scale production of the COVID-19 vaccine candidates. Fujifilm Diosynth Biotechnologies will produce bulk drug substance of NVX‑CoV2373, Novavax’ vaccine candidate, which began phase 3 clinical testing in the U.S. and Mexico in December, 2020. NVX-CoV2373- is already being manufactured at commercial scale at the company’s plant in Morrisville, North Carolina. “After several months of intense preparation and hard work, we are ready to produce two vaccine candidates locally here in College Station,” said Gerry Farrell, chief operating officer, Fujifilm Diosynth Biotechnologies, Texas. “We are pleased to bring our technical expertise and world-class facilities to support the mission of Operation Warp Speed in bringing a safe and effective vaccine to the world.” John Sharp, chancellor of The Texas A&M System, said, “The Texas A&M System is proud to be part of this unprecedented manufacturing effort. Our partnership with Fujifilm Diosynth Biotechnologies confirms the importance of the CIADM program for Texas, the nation and the world.” Fujifilm Diosynth Biotechnologies owns and operates three facilities built through the CIADM program. As a subcontractor of the Texas A&M System, the facilities can be made available for emergency government use. In July, the federal government reserved capacity at the College Station facility through the end of 2021 by tapping into an agreement with the CIADM. To enhance vaccine production, Fujifilm Diosynth Biotechnologies accelerated its planned capacity expansion investments in the facility by several months. The facility is the largest scale-out cell culture manufacturing facility in the U.S. with a total of 14 2,000L cell culture trains. To prepare for mass production of the vaccine candidates, Fujifilm Diosynth Biotechnologies has added about 260 positions since April 2020, doubling its local workforce. The company plans to recruit another 50 positions. “Our team has worked around the clock since July and we’re starting to see light at the end of the tunnel,” Farrell said. “There is great pride and satisfaction on our team for being part of the solution to the pandemic.” The CIADM contract is with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS). “This is a tremendous responsibility,” said W. Jay Treat, Texas A&M’s chief manufacturing officer for the CIADM. “It’s gratifying for us to make a positive contribution in fighting the pandemic.” Operation Warp Speed is a partnership among components of the HHS, the Department of Defense and other federal agencies, engaging with private firms, and coordinating among existing HHS-wide efforts to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !